@article {KREIENBRING3619, author = {KATRIN KREIENBRING and ANNIKA FRANZ and ROLF RICHTER and DUSKA DRAGUN and HARALD HEIDECKE and DOMINIK M{\"U}LLER and MONIKA MENTZE and RALF DECHEND and JALID SEHOULI and ELENA IOANA BRAICU}, title = {The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer}, volume = {38}, number = {6}, pages = {3619--3625}, year = {2018}, doi = {10.21873/anticanres.12636}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: This study aimed to analyze the predictive, prognostic and diagnostic value of autoantibodies to coagulation factor II thrombin receptor (F2R; protease-activated receptor 1, PAR1) (PAR1-AB) in patients with primary epithelial ovarian cancer (EOC). Materials and Methods: A total of 197 patients with primary EOC and 200 healthy female blood donors were included in the study. Enzyme-linked immunosorbent assay was applied to determine PAR1-AB levels in blood sera taken preoperatively. Correlation of PAR1-AB with clinicopathological outcome, progression-free (PFS) and overall (OS) survival was analyzed and patients were compared with controls. Results: PAR1-AB was significantly negatively correlated with histological grading (p=0.008) and was significantly lower in the patient group compared to healthy controls (p\<0.001). There was no significant correlation of PAR1-AB level with PFS or OS. Conclusion: This study showed PAR1-AB to significantly decrease in patients with primary EOC and with histological high-grade carcinoma. The relevance of PAR1-AB in early detection of ovarian cancer and follow-up for EOC should be further investigated.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/6/3619}, eprint = {https://ar.iiarjournals.org/content/38/6/3619.full.pdf}, journal = {Anticancer Research} }